DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Kelley RK, Gane E, Assenat E. et al.
A phase 2 study of galunisertib (TGF-β1 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma.
Clin Transl Gastroenterol 2019;
10 (07) e00056
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.